- Fingolimod, sold
under the
brand name
Gilenya, is an
immunomodulating medication, used for the
treatment of
multiple sclerosis.
Fingolimod is a sphingosine-1-phosphate...
-
Fingolimod (
Gilenya) was
approved in 2010 by the FDA for MS. In 2015, the
first case of PML and a case of "probable PML" were
reported by two
Gilenya users...
-
Biogen Oral 50% 0.15
Vumerity Diroximel fumarate Biogen Oral 50% 0.11-0.15
Gilenya Fingolimod Oral 50% 0.22-0.25
Zeposia Ozanimod [better source needed] Oral...
- Asthma, COPD
Galvus (vildagliptin)
Diabetes mellitus type 2 910 2012 39%
Gilenya (fingolimod)
Multiple sclerosis 1,195 2012 142% Gleevec/Glivec (imatinib)...
- of PML. The
boxed warning had been
included for the
drugs Tecfidera and
Gilenya, both of
which have had
incidences of PML
resulting in death.[citation...
- sclerosis,
after four
years of
using fingolimod (also
known by its
brand name
Gilenya),
another drug used to
treat relapsing forms of
multiple sclerosis, she...
- the
clinical work
performed during development of
fingolimod (trade name
Gilenya), a non‐selective S1P modulator.[better source needed] The
prospects for...
- (Bafiertam),
approved in
April 2020. Four S1P modulators:
Fingolimod (
Gilenya), an oral
treatment and the
first oral
therapy approved for
multiple sclerosis...
-
billion Interferon beta 1a
Rebif Merck KGaA 4 $1.93
billion Fingolimod Gilenya Novartis 5 $1.41
billion Natalizumab Tysabri Biogen Idec 6 $1.38 billion...
-
Lilly and Company,
Lilly Icos
Erectile dysfunction Nov-2002 2017-Nov 52
Gilenya fingolimod 272,701 4.05%
Novartis Corporation Multiple sclerosis Feb-2000...
